The $6.4B Milestone Trap, How 36 Days Erased the Celgene CVR

Late-2010s US pharma M&A was overwhelmingly about patent cliff avoidance. Pfizer, Allergan, AbbVie, Merck, and BMS all faced staggered LOE schedules on flagship drugs and turned to external pipeline M&A. The persistent negotiation friction was how to price the clinical-development uncertainty of biotech pipeline assets, and CVRs (Contingent Value Rights) had been used sporadically since the 1980s as the standard tool. CVRs pay additional consideration upon achievement of milestones (clinical, regulatory, or commercial) and are commonly used to bridge 5~15% of the headline price as a contingent layer. Notable precedents: Sanofi-Genzyme (2011), Sanofi-Bioverativ (2018), Allergan-Tobira (2016). The structures vary across deals, but typically each milestone has its own payment tranche, with partial milestone achievement triggering partial payment.

What made the BMS-Celgene CVR exceptional was its all-or-nothing design, all three milestones had to land in time for any payment. The conventional CVR structure assigns a separate payment tranche to each milestone so that partial achievement yields partial payment. BMS's insistence on combined-condition payment created an asymmetric option where a single missed deadline could erase the entire $6.4B notional. In hindsight, that drafting choice was the single most consequential element of the transaction.

Celgene was a New Jersey based biopharmaceutical company spun out of Celanese Corporation in 1986. In 1998 it pivoted to oncology and immunology by rediscovering thalidomide's clinical activity in multiple myeloma, building a franchise that became the foundation of the company. Core revenue drivers as of 2018: Revlimid (lenalidomide, first-line multiple myeloma), Pomalyst (pomalidomide, third-line multiple myeloma), Otezla (apremilast, psoriasis and psoriatic arthritis), plus late-stage pipeline assets Ozanimod (multiple sclerosis), Liso-cel (CAR-T for large B-cell lymphoma), and Ide-cel (CAR-T for multiple myeloma). Revlimid alone accounted for roughly 63% of FY2018 revenue, and Revlimid's US patent estate faced staggered LOE between 2022 and 2026, making "post-Revlimid" the existential question for the company.

The transaction was structured as a reverse triangular merger. BMS formed a wholly owned subsidiary, Burgundy Merger Sub, Inc., which merged with and into Celgene, leaving Celgene as the surviving entity and a wholly owned subsidiary of BMS. Each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR. At the announcement-date BMS closing price, the per-share consideration was approximately $102.43, implying total enterprise value of approximately $74B including Celgene net debt. Financing came from a combination of BMS balance sheet cash, a $33.5B syndicated bridge loan facility (Morgan Stanley and MUFG lead arrangers), and a subsequent investment-grade bond offering.

Both sides ran full-line megadeal advisor lineups. On the BMS side, Morgan Stanley and Evercore co-led financial advisory, with Kirkland & Ellis as lead legal counsel driving the transaction structure and CVR drafting. On the Celgene side, J.P. Morgan and Citi led financial advisory, with Wachtell, Lipton, Rosen & Katz as lead legal counsel. In the post-close CVR litigation, Skadden, Arps appears as lead defense counsel for BMS, while plaintiff-side representation includes Bernstein Litowitz Berger & Grossmann (Mark Lebovitch et al.) for the former Celgene shareholders through trustee UMB Bank.

Note: Advisor information is based on official announcements, S-4 filings, and court records. Some assignments are not confirmed beyond SEC or court filings.

Unit: USD millions | US GAAP consolidated | Source: Celgene 10-K filings (FY2014~FY2018). R&D expense is reported separately from SG&A and is incorporated into operating income via separate adjustment.

Per-share consideration at the announcement-date BMS closing price ($52.43 on Jan 2, 2019) was $50 cash + $52.43 in BMS stock + CVR option value ~$1~$3 = approximately $102.43. The CVR's announcement-date option value was estimated by sell-side analysts at $1~$3 using standard Black-Scholes and trinomial-tree approaches. The CVR briefly traded above $2.50 at NYSE listing in November 2019 before collapsing to $0.05 by late 2020 as Breyanzi delay concerns mounted, expiring at $0 on December 31, 2020. The headline EV/EBITDA multiple was approximately 11.0x (EV $74B / FY2018 EBITDA $6.74B), seen as a premium multiple given the Revlimid LOE overhang.

Note: Pricing figures are based on SEC S-4 filings, press coverage, and market estimates. Some option values are estimates.

The transaction closed on November 20, 2019, and the CVR expired worthless on December 31, 2021. Ozanimod and Ide-cel (Abecma) achieved FDA approval within their deadlines, but Liso-cel (Breyanzi) missed its December 31, 2020 deadline by 36 days, approved February 5, 2021, triggering the all-or-nothing clause and erasing the entire ~$6.4B contingent obligation. Shortly thereafter, trustee UMB Bank filed a $6.4B class-action suit in SDNY federal court (UMB Bank, N.A. v. Bristol-Myers Squibb Company, 1:21-cv-04897), alleging that BMS breached its "diligent efforts" obligation by allowing a major BLA amendment that added at least three months of review time and by allowing manufacturing inspection delays. On September 30, 2024, SDNY ruled in BMS's favor on the merits (plaintiffs failed to establish the intentional-delay theory), and plaintiffs appealed. A separate class action was refiled in 2024~2025; certain claims were dismissed, others survived motion to dismiss. As of May 2026, no final non-appealable judgment exists. Separately, Revlimid US LOE began in 2022 and accelerated through 2025, leaving BMS revenue growth below market expectations and the stock trading roughly sideways from 2019 levels.